PG
HZNP

PEAK6 Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PEAK6 Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,999
Closed -$109K – 5301
2016
Q3 		$109K Buy
+5,999
New +$117K ﹤0.01% 3536
2016
Q1 		– Sell
-30,100
Closed -$527K – 5340
2015
Q4 		$652K Buy
+30,100
New +$586K ﹤0.01% 2317

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PEAK6 Group's HZNP Position: Q4 2016 in Review

PEAK6 Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 5,999 shares — an estimated $109K sold.

PEAK6 Group first reported a position in HZNP in Q4 2015 and held it in 2 quarters. The position peaked at $652K in Q4 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

  • PEAK6 Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
  • PEAK6 Group sold 5,999 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $109K.
  • PEAK6 Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 2 quarters.
  • PEAK6 Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $652K in Q4 2015.
  • 234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on PEAK6 Group's 13F filing for Q4 2016, filed 13 Feb 2017.